Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2016 / Articles / Nov / Determining fluorescence Limit of Detection with Nanoparticle Tracking Analysis
Discovery & Development Business Practice Drug Delivery Small Molecules Technology and Equipment Advanced Medicine Analytical Science Trends & Forecasts Drug Delivery Small Molecules Facilities & Equipment Technology & Manufacturing Cell & Gene

Determining fluorescence Limit of Detection with Nanoparticle Tracking Analysis

11/23/2016 1 min read

Share

Introduction

Introduction

The ability to detect nanoparticle fluorescence is important when attempting to distinguish a particular subset of particles from within a complex background. Particles which are fluorescent can be measured in terms of particle size and concentration to understand the nature of those particles. A typical application for this is in understanding the fate of drug delivery vectors as well as understanding the toxicology of nanoparticles in biological environments. Alternatively, fluorescently labeled antibodies may be used to bind specifically to target particles within a sample, thus providing a mechanism to identify specific particle populations within an unknown sample. This has implications in diagnostic applications such as research into exosomes and microvesicles,  where specific markers can be identified and monitored in the detection of disease. Nanoparticle Tracking Analysis (NTA), available on the NanoSight range of instruments, can operate in light scatter mode where all particles within a sample are visualized and measured (and thus does not require the sample to be fluorescently labeled to take a measurement). Alternatively, the instruments can also operate in fluorescence mode where only fluorescently labeled particles are detected and measured.

The NanoSight system uses either a 405 nm (violet), 488 nm (blue) or 532 nm (green) laser source to excite particles labelled with appropriate fluorophores, whose fluorescence can then be determined using suitably matched long or short-pass filters. This application note works through an experiment to approximately establish a baseline in terms of the fluorescence limit of detection for a given fluorophore. The biotin-streptavidin interaction is known to be a very strong non-covalent binding interaction, Kd ~10-14 mol/L. Each streptavidin molecule has 4 available sites for biotin binding, one for each of the monomer units that comprise the quaternary structure. This ratio was used to calculate a maximum possible number of fluorescent streptavidin molecules that each gold nanoparticle could have bound to the surface.  >> Download the full Application Note as PDF

Malvern Instruments provides the materials and biophysical characterization technology and expertise that enable scientists and engineers to understand and control the properties of dispersed systems. These systems range from proteins and polymers in solution, particle and nanoparticle suspensions and emulsions, through to sprays and aerosols, industrial bulk powders and high concentration slurries. Used at all stages of research, development and manufacturing, Malvern’s materials characterization instruments provide critical information that helps accelerate research and product development, enhance and maintain product quality and optimize process efficiency. Our products reflect Malvern’s drive to exploit the latest technological innovations and our commitment to maximizing the potential of established techniques. They are used by both industry and academia, in sectors ranging from pharmaceuticals and biopharmaceuticals to bulk chemicals, cement, plastics and polymers, energy and the environment. Malvern systems are used to measure particle size, particle shape, zeta potential, protein charge, molecular weight, mass, size and conformation, rheological properties and for chemical identification, advancing the understanding of dispersed systems across many different industries and applications. Headquartered in Malvern, UK, Malvern Instruments has subsidiary organizations in all major European markets, North America, Mexico, China, Japan and Korea, a joint venture in India, a global distributor network and applications laboratories around the world. www.malvern.com severine.michel@malvern.com

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.